References
- McTavish D, Sorkin EM. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1989; 38: 19–76
- Kenny J. Calcium channel blocking agents and the heart. Br Med J Clin Res Ed 1985; 291: 1150–1152
- Ramoska E A, Spiller H A, Winter M, Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med 1993; 22: 196–200
- Litovitz T L, Holm K C, Clancy C. 1992 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1993; 11: 494–555
- Howarth D M, Dawson A H, Smith A J, Buckley N, Whyte IM. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol 1994; 13: 161–166
- Buckley N, Dawson A H, Howarth D, Whyte IM. Slow-release verapamil poisoning. Use of polyethylene glycol whole-bowel lavage and high-dose calcium. Med J Aust 1993; 158: 202–204
- Buckley N A, Whyte I M, Dawson AH. Overdose with calcium channel blockers. BMJ 1994; 308: 1639
- Neuvonen P J, Olkkola KT. Oral activated charcoal in the treatment of intoxications. Role of single and repeated doses. Med Toxicol Adverse Drug Exp 1988; 3: 33–58
- Dawling S P, Crome P, Braithwaite R. Effect of delayed administration of activated charcoal on nortriptyline absorption. Eur J Clin Pharmacol 1978; 14: 445–447
- Neuvonen P J, Elfving S M, Elonen E. Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. Eur J Clin Pharmacol 1978; 13: 213–218
- Neuvonen P J, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 1980; 17: 51–57
- Olkkola K T, Neuvonen PJ. Do gastric contents modify antidotal efficacy of oral activated charcoal. Br J Clin Pharmacol 1984; 18: 663–669
- Scheinin M, Virtanen R, Iisalo E. Effect of single and repeated doses of activated charcoal on the pharmacokinetics of doxepin. Int J Clin Pharmacol Ther Toxicol 1985; 23: 38–42
- Lim D T, Singh P, Nourtsis S, Dela-Cruz RD. Absorption inhibition and enhancement of elimination of sustained-release theophylline tablets by oral activated charcoal. Ann Emerg Med 1986; l5: 1303–1307
- Kirschenbaum L A, Mathews S C, Sitar D S, Tenenbein M. Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther 1989; 46: 264–271
- Ferner R E, Odemuyiwa 0, Field A B, Walker S, Volans G N, Bateman DN. Pharmacokinetics and toxic effects of diltiazem in massive overdose. Hum Toxicol 1989; 8: 497–499
- Hynning P-Å, Anderson P, Bondesson U, Boreus LO. Liquid-chromatographic quantification compared with gas-chromatographic-mass-spectrometric determination of verapamil and norverapamil in plasma. Clin Chem 1988; 34: 2502–2503
- Salama Z B, Dilger C, Czogalla W, Otto R, Jaeger H. Quantitative determination of verapamil and metabolites in human serum by high-performance liquid chromatography and its application to biopharmaceutic investigations. Arzneimittelforschung 1989; 39: 210–215
- Crome P, Dawling S, Braithwaite R A, Masters J, Walkey R. Effect of activated charcoal on absorption of nortripyline. Lancet 1977; 2: 1203–1205
- Jawary D, Cameron P A, Dziukas L, McNeil JJ. Drug overdose-reducing the load. Med J Aust 1992; 156: 343–346
- Laine K, Kivistö KT, Laakso I, Neuvonen PJ. Prevention of amlodipine absorption by activated charcoal; effect delay in charcoal administration. Br J Clin Pharmacol 1997; 43: 29–33
- MacDonald D, Alguire PC. Case report: Fatal overdose with sustained-release verapamil. Am J Med Sci 1992; 303: 115–117